RxDoctor Payments Data

Ahmad Awan, MD

Cardiovascular Disease · Lake Charles, LANPI 1831573013

Payments from drug & device makers

What this record shows

22 manufacturers reported payments, led by Abbott at 33.4% of the total. 2025 is the largest year on record at $6,345, 3.8 times the $1,659 reported in 2019.

$13,359in general payments, 2019–2025

Across 162 payments — averaging $82.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Medtronic$2K
  • Boston Scientific$2K
  • Terumo Medical Corporation$2K
  • Cardiovascular Systems Inc.$597
  • Shockwave Medical, Inc$578
  • plus $2K from 16 others

What the payments were for

  • Travel & lodging$6,97552%
  • Food & beverage$6,38448%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,359 in reported general payments places this provider in the 85th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$356,787
Medicare patients
1,600
Services billed
4,576

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban155$130,038
Repatha SureclickEvolocumab103$60,756
EntrestoSacubitril/Valsartan61$51,477
XareltoRivaroxaban41$33,683
Metoprolol Succinate185$2,419
Atorvastatin Calcium160$2,341
Prasugrel Hcl36$1,729
Ranolazine ErRanolazine21$1,700
Rosuvastatin Calcium134$1,683
ClopidogrelClopidogrel Bisulfate220$1,629
Amiodarone Hcl34$1,206
Isosorbide Mononitrate ErIsosorbide Mononitrate94$743
Amlodipine Besylate116$684
Pantoprazole Sodium58$489
Nifedipine ErNifedipine32$486

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$73$130,038155 claims
NovartisEntresto$294$51,47761 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Lake Charles

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →